公开(公告)号：US20220211718A1

公开(公告)日：2022-07-07

申请号：US17609874

申请日：2020-05-11

申请人： LES LABORATOIRES SERVIER ,  NOVARTIS AG

发明人： James Brooke MURRAY ,  Frèdéric COLLAND ,  Audrey CLAPERON

IPC分类号： A61K31/5377 ,  A61P35/02

摘要： The invention relates to a Bcl-2 inhibitor for use in the treatment of a Bcl-2 mediated cancer carrying at least 1, 2, 3, 4, 5 or all of the following mutations: (i) Gly101Val; (ii) Asp103Tyr; (iii) Asp103Val; (iv) Asp103Glu; (v) Arg129Leu and (vi) Ala113Gly; wherein the Bcl-2 inhibitor is N-(4-hydroxyphenyl)-3-{6-[((3S)-3-(4-morpholinylmethyl)-3,4-dihydro-2(1H)-isoquinolinyl)carbonyl]-1,3-benzodioxol-5-yl}-N-phenyl-5,6,7,8-tetrahydro-1-indolizine carboxamide (Compound A) or 5-(5-chloro-2-{[(3S)-3-(morpholin-4-ylmethyl)-3,4-dihydroisoquinolin-2(1H)-yl]carbonyl}phenyl)-N-(5-cyano-1,2-dimethyl-1H-pyrrol-3-yl)-N-(4-hydroxyphenyl)-1,2-dimethyl-iH-pyrrole-3-carboxamide (Compound B), or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20190240225A1

公开(公告)日：2019-08-08

申请号：US16318925

申请日：2017-07-21

申请人： LES LABORATOIRES SERVIER ,  NOVARTIS AG

发明人： Andrew WEI ,  Donia MOUJALLED ,  Giovanna POMILIO ,  Ana Leticia MARAGNO ,  Olivier GENESTE ,  Audrey CLAPERON ,  Heiko MAACKE ,  Ensar HALILOVIC ,  Dale PORTER ,  Erick MORRIS ,  Youzhen WANG ,  Sneha SANGHAVI ,  Prakash MISTRY

IPC分类号： A61K31/519 ,  A61K31/4725 ,  A61P35/02

CPC分类号： A61K31/519 ,  A61K9/0019 ,  A61K9/0053 ,  A61K31/407 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/55 ,  A61K31/675 ,  A61K45/06 ,  A61P35/02

摘要： A combination comprising a BCL-2 inhibitor and a MCL1 inhibitor, and compositions and uses thereof.